Tjoapack Boosts Bottle Packaging Capabilities at Netherlands Facility
Tjoapack is expanding its oral solid dose (OSD) bottle packaging capabilities at its Etten-Leur, Netherlands, facility with a new state-of-the-art Cremer Uhlmann IBC 50 line, enhancing flexibility, efficiency, and GMP-compliant packaging options to meet growing global demand for pharmaceutical and biologic products.
Tjoapack, a global contract packaging organization, is expanding its critical OSD bottle packaging capabilities at its Etten-Leur facility in the Netherlands with a second production line, a state-of-the-art Cremer Uhlmann IBC 50 line. This addition enables Tjoapack to serve a broader range of customer needs with enhanced efficiency and compliance.
The new line automates bottle packaging, enabling the packaging of any bottle shape and filling up to 50 bottles per minute. The investment comes at a time of significant growth in the pharmaceutical bottle packaging market, driven by rising demand for OSD medications and increasing requirements for flexible, compliant packaging solutions. By expanding its bottle packaging capabilities, Tjoapack is well-positioned to support pharmaceutical companies as they scale up production and respond to evolving market needs.
“This investment reflects our continued focus on flexibility and operational excellence,” said Geert Vleugels, General Manager of Tjoapack Netherlands. “By introducing a line that supports multiple packaging configurations, we can better align our services with the diverse needs of our customers while maintaining the highest GMP standards.”
The expansion forms part of Tjoapack’s ongoing investment in infrastructure and technology designed to strengthen service capabilities and ensure consistent quality, compliance, and reliability for pharmaceutical partners worldwide. This includes recent investments in expanding its cold chain and injectable packaging capabilities across the United States and the Netherlands, strategic moves aimed at meeting the growing global demand for biologics and temperature-sensitive therapies.


















